Mark Lebwohl, MD

This review describes the impact of nonmedical switching of biologic therapies on US patients and providers, with a focus on switching to in-class alternatives.

The panel details the clinical and economic burden when patients switch between agents in plaque psoriasis.

Bhavesh Shah, PharmD, and Robert Groves, MD, discuss the priorities payers should be taking into account when managing psoriasis treatment.